JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wong, C. O.
Right arrow Articles by Larson, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wong, C. O.
Right arrow Articles by Larson, S. M.
Journal of Nuclear Medicine Vol. 46 No. 10 1765-1766
© 2005 by Society of Nuclear Medicine

JNM Supplement on Molecular Radiotherapy

C. Oliver Wong, MBBS, PhD, MD

William Beaumont Hospital Royal Oak, Michigan

TO THE EDITOR: I have read the recent JNM supplement on the clinical practice of molecular radiotherapy (1) with great interest and enthusiasm. The editors have done a superb job of bringing out the importance of radiotherapy, besides PET/CT molecular imaging, in the future growth of nuclear medicine. There are comprehensive sections on radiodosimetry, oral treatments, and various intravenous treatments. But there appears to be an omission in the area of emerging intraarterial treatments, such as 90Y-microspheres for hepatocellular and metastatic liver cancers (2–5). Because nuclear medicine is a part of intraarterial interventional radiologic or surgical procedures, it may be important for readers to be aware of the possibility that such procedures may offer a vast integral opportunity in the future. In addition, because nuclear medicine procedures such as PET, PET/CT, arterial 99mTc-macroaggregated albumin scans, multiple gated acquisitions, and bone scans are often used in both initial treatment planning and subsequent monitoring of response, a separate section on these aspects would also have been enlightening to our profession.

REFERENCES

  1. Larson SM, Krenning EP, eds. Clinical practice of molecular radiotherapy. J Nucl Med. 2005;46(suppl):1S–204S.[Free Full Text]
  2. Ho S, Lau WY, Leung TWT, Chan M, Johnson PJ, Li AKC. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med. 1997;24:293–298.[Medline]
  3. Dancey JE, Shepherd FA, Paul K, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med. 2000;41:1673–1681.[Abstract/Free Full Text]
  4. Gray BN, Anderson JE, Burton MA, van Hazel G, Codde J, Morgan C, Klemp P. Regression of liver metastases following treatment with yttrium-90 microspheres. Aust N Z J Surg. 1992;62:105–110.[Medline]
  5. Wong CY, Salem R, Qing F, et al. Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET. J Nucl Med. 2004;45:1892–1897.[Abstract/Free Full Text]
 

REPLY:

Neeta Pandit-Taskar, MD and Steven M. Larson, MD

Memorial Sloan-Kettering Cancer Center, New York, New York

We appreciate the comments from Dr. Wong regarding radiotherapy with 90Y-microspheres. As Dr. Wong quite rightly points out, the lack of a chapter on 90Y-microspheres within our supplement (1) was an omission, which should be corrected in the future, since the product (SIR-Spheres; Sirtex Medical Limited) has been approved for use in the United States.

This therapy provides an alternative to radiation or chemotherapy in nonresectable cases of liver cancer. Unlike external-beam radiation, which can harm normal tissue, this method takes advantage of the greater arteriolar density of hepatic tumors for selective delivery of radiation via microspheres that become trapped in the tumor microcirculation. Significantly greater radiation exposure to the tumor results from this method than from external irradiation, with little damage to the normal tissue. Many liver tumors, including carcinoid, are quite sensitive to radiation and highly suitable for this therapy. A number of studies done abroad have shown the usefulness of 90Y-microspheres and 131I-Lipiodol in the treatment of inoperable hepatocellular carcinoma, prevention of recurrence, and improvement of prognosis and survival in patients with hepatocellular carcinoma (2–4).

90Y-Microspheres were evaluated in a phase I study to assess safety and therapeutic benefit with absorbed raidiation dose ranging from 50 to 150 Gy in patients with unresectable hepatocellular carcinoma or with carcinoma metastatic to the liver (colorectal, neuroendocrine, carcinoid, islet cell tumors) (5–7). The use of SIR-Spheres in combination with chemotherapy has been shown useful for metastatic colorectal carcinoma (8,9) and has been approved by the U.S. Food and Drug Administration. Another commercial product is TheraSpheres (Theragenics).

In the past, the approved uses of these products were restricted; however, with increasing evidence of the effectiveness of therapy, their use is likely to grow. Further discussion and a comprehensive review of this topic will greatly enhance the awareness of this therapy. We support and recommend publication of a focused review on 90Y-microspheres.

REFERENCES

  1. Larson SM, Krenning EP, eds. Clinical practice of molecular radiotherapy. J Nucl Med. 2005;46.(suppl):1S–204S.
  2. Leung WT, Lau WY, Ho S, et al. Selective internal radiation therapy with intra-arterial iodine-131-Lipiodol in inoperable hepatocellular carcinoma. J Nucl Med. 1994;35:1313–1318.[Abstract/Free Full Text]
  3. Lau WY, Ho S, Leung WT, Chan M, Lee WY, Johnson PJ. What determines survival duration in hepatocellular carcinoma treated with intraarterial yttrium-90 microspheres? Hepatogastroenterology. 2001;48:338–340.[Medline]
  4. Dancey JE, Shepherd FA, Paul K, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med. 2000;41:1673–1681.
  5. Houle S, Yip TK, Shepherd FA, et al. Hepatocellular carcinoma: pilot trial of treatment with Y-90 microspheres. Radiology. 1989;172:857–860.[Abstract/Free Full Text]
  6. Herba MJ, Illescas FF, Thirlwell MP, et al. Hepatic malignancies: improved treatment with intraarterial Y-90. Radiology. 1988;169:311–314.[Abstract/Free Full Text]
  7. Andrews JC, Walker SC, Ackermann RJ, Cotton LA, Ensminger WD, Shapiro B. Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. J Nucl Med. 1994;35:1637–1644.[Abstract/Free Full Text]
  8. Van Hazel G, Blackwell A, Anderson J, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol. 2004;88:78–85.[Medline]
  9. Gray B, Van Hazel G, Hope M, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001;12:1711–1720.[Abstract/Free Full Text]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wong, C. O.
Right arrow Articles by Larson, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wong, C. O.
Right arrow Articles by Larson, S. M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE